Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era. - Test2 - elhamkhani - TriplyDB

Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.

Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.

http://www.wikidata.org/entity/Q37989571

about

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study Prostate cancer vaccines: an old yet novel target, the androgen receptor.A decade of cell therapy clinical trials (2000-2010).Cancer vaccine: learning lessons from immune checkpoint inhibitors.

P2860

Q35746834-BE27A926-8D3E-4F4D-856D-60AE21F8B5FE Q45726626-67B0C2C2-292E-48D8-ACCF-2441899A572B Q48413558-E1C5A7DD-C65B-4E86-9635-A41870DB31E2 Q49260236-4582EE21-5874-4320-85BC-608DDBBED872

P2860

Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.

http://www.wikidata.org/entity/Q37989571

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Prostate cancer vaccines: movi ...... ward in the post-Provenge era.

@en

Prostate cancer vaccines: movi ...... ward in the post-Provenge era.

@nl

type

label

Prostate cancer vaccines: movi ...... ward in the post-Provenge era.

@en

Prostate cancer vaccines: movi ...... ward in the post-Provenge era.

@nl

prefLabel

Prostate cancer vaccines: movi ...... ward in the post-Provenge era.

@en

Prostate cancer vaccines: movi ...... ward in the post-Provenge era.

@nl

P1433

Q37989571-8B382B8D-60B2-49AA-B4ED-3F3F72CADFD9

P1476

Q37989571-6B92357F-F228-4AF4-8966-526578DFB74C

P2093

Q37989571-1C971D8A-5A5E-4BD7-8CD9-5297BD52EBC0

Q37989571-2A7C4468-8F92-4FF3-9E43-5AD8608A3AE6

P2860

Q37989571-0636ACD0-9005-4AD8-B519-763D45DD043A

Q37989571-08654490-9750-4C0F-BA35-A4AC618DA115

Q37989571-08E0AB8C-B528-4FD9-A1BB-31C5923553E9

Q37989571-0A4CE1F6-4450-43E8-922D-36F537CAF06D

Q37989571-0D30E8A1-2FBE-4901-8CA0-787AF5917597

Q37989571-18FF9ED5-4733-4F7C-9F68-8C4246B93974

Q37989571-1C13F369-2F6D-4E20-A3EC-C184D9B816D6

Q37989571-1E9B0AA8-453B-4D57-84B5-11E4E64A08B3

Q37989571-229E8F70-C619-4751-A60F-3D3E6D7FD098

Q37989571-26F24309-2832-49B3-BADE-07AF55F70858

P304

Q37989571-72358DA8-45FD-4E05-AC7E-6E93EFEF1682

P31

Q37989571-2CF85919-A4B9-4A9A-8946-368C4DD38C9C

P356

Q37989571-1C61DF38-9E47-49B7-9A42-7A2748C64949

P433

Q37989571-84941F9F-FFCC-4B76-AD1F-C24153C8C3AB

P478

Q37989571-2E9CB305-8FC1-46BE-AE84-1AF0FD593270

P577

Q37989571-3698C3AD-2669-49D7-854E-9353A66D990A

P698

Q37989571-5E77A4B8-6D1A-444A-8B8E-4267FCEB7C65

P356

P1433

Expert Review of Vaccines

P1476

Prostate cancer vaccines: movi ...... ward in the post-Provenge era.

@en

P2093

Lauren V Wood

http://www.w3.org/2001/XMLSchema#string

Philip M Arlen

http://www.w3.org/2001/XMLSchema#string

P2860

Improved endpoints for cancer immunotherapy trials

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

P304

287-302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERV.11.183

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22380822

http://www.w3.org/2001/XMLSchema#string